COPENHAGEN (Reuters) - Danish biotech Genmab, which has seen its shares rocket 163 percent this year, is set for further gains as new research data showed increased potential for its Darzalex blood cancer treatment, analysts said on Wednesday.
http://ift.tt/xePdMM
from Reuters: Health News
via
animenewspro
Aucun commentaire:
Enregistrer un commentaire